Stoke Therapeutics (STOK) Assets Average (2019 - 2026)

Stoke Therapeutics has reported Assets Average for 8 years, with the latest figure at $430.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 27.01% year-over-year to $430.9 million; the trailing twelve-month figure through Mar 2026 stood at $430.9 million (up 27.01% YoY), and the FY2025 full-year result was $345.0 million, up 38.03% from the prior year.
• Assets Average for Q1 2026 stood at $430.9 million, up from $389.3 million in the prior quarter.
• The five-year high for Assets Average was $430.9 million in Q1 2026, with the low at $216.8 million in Q1 2024.
• Average Assets Average over 5 years is $302.8 million, with a median of $282.4 million recorded in 2024.
• Year-over-year, Assets Average dropped 19.4% in 2024 and soared 56.49% in 2025.
• Tracing STOK's Assets Average over 5 years: stood at $266.8 million in 2022, then retreated by 12.27% to $234.1 million in 2023, then advanced by 20.64% to $282.4 million in 2024, then surged by 37.85% to $389.3 million in 2025, then increased by 10.66% to $430.9 million in 2026.
• The last three Assets Average figures came in at $430.9 million (Q1 2026), $389.3 million (Q4 2025), and $372.4 million (Q3 2025), per Business Quant data.

Peer Comparison